Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells
LM Souza, Karl Welte(University Children's Hospital Tübingen), VR Chazin, Joan Bruszewski(Amgen (United States)), DC Murdock, PH Lai, Chen Kk, Jean M. Barendt(Amgen (United States)), Janice Gabrilove(Memorial Sloan Kettering Cancer Center), Roland Mertelsmann(Unknown), E Platzer(Friedrich-Alexander-Universität Erlangen-Nürnberg), Malcolm A.S. Moore(Memorial Sloan Kettering Cancer Center), H.S. Lu, KM Zsebo, TC Boone
Cited by 197
Related Papers
Recombinant Human Granulocyte Colony-Stimulating Factor: Effects on Normal and Leukemic Myeloid Cells
|Science|1986|1.2k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor.
|Proceedings of the National Academy of Sciences|1985|522
Epidemiology of non-Hodgkin?s lymphoma (NHL): trends, geographic distribution, and etiology
|Annals of Hematology|2004|488